Date/heure
Date(s) - 05 Déc. 2023 - 06 Déc. 2023
Toute la journée
This virtual conference organized by EACR and AstraZeneca will take place on December 5 and 6, 2023 and will focus on basic and clinical aspects of targeting a broad panel of epigenetic proteins in cancer, either as monotherapies, or as combination therapies, including the use of immune checkpoint inhibitors to increase drug sensitivity and overcome chemoresistance.
Target audience:
Scientists in academia and industry who are interested in how Epigenetic targeted therapy can be used for genetically targeted and combination therapies, including immune-based cancer therapies. The conference will focus on the mechanistic aspects of gene regulation and cellular plasticity, drug development as well as clinical trials using epigenetic targeted therapies.
Topics to be covered:
- Epigenetic Regulation in Cancer Development and Maintenance
- Novel Epigenetic Targets
- Drug Resistance
- Combination Therapies
- Clinical Trials
- Deadline for abstract submission: October 9th 2023, 23:59 CET
- Deadline for registration: November 13th 2023, 23:59 CET
Catégories